Only a few companies in Japan! Identifying the transcription start point of mRNA! A new quantitative analysis technology that can analyze quickly and at low cost.
"CAGE" is a technology that allows for the quantification of gene transcription products at each transcription start site and enables genome-wide quantitative analysis of promoter activity. This allows for the accurate capture of transcriptional promoters and facilitates detailed profiling of expression. It serves as a powerful tool in genome annotation research from a new perspective, such as elucidating the cascade of transcriptional signal transduction. [Features] ■ High sensitivity technology ■ Large-scale and rapid analysis ■ Low cost ■ Excellent quantitativeness ■ Potential to discover new RNA molecules and promoters *For more details, please refer to the catalog or feel free to contact us.
Inquire About This Product
basic information
【Sequencing】 ■NGS: NextSeq ■Recommended sample number: 6 to 16 mix / lane ■Average data volume: Approximately 20 million reads/sample ■Sequence: 75bp Single-end ■Data analysis: Included in the analysis price. Can also be analyzed using the free analysis pipeline of the National Institute of Genetics. ■Delivery time: 4 to 6 weeks *For more details, please refer to the catalog or feel free to contact us.
Price range
P2
Delivery Time
※Usually 4 to 6 weeks.
Applications/Examples of results
For more details, please refer to the catalog or feel free to contact us.
catalog（1）
Download All Catalogs
Company information
Danaform Inc. is a company established in 1998, based on the RIKEN Venture System of the National Research and Development Agency RIKEN, with Yoshihide Hayasaki from RIKEN (who has been the representative director of Danaform Inc. since 2021) at its core. The company is actively engaged in gene analysis and genetic testing, focusing on technologies co-developed by Danaform and RIKEN, including contract analysis using next-generation sequencers such as CAGE-seq and RNA-seq, the sale of fluorescent reagents Eprobe capable of SNP detection, and the sale of various clones, boasting a significant inventory. Moving forward, we aim to refine our proprietary technologies and strive for higher quality research and manufacturing as experts in the field of genetics, with the hope of contributing to people's health.
